R&D channel feed – Endpoints News

R&D channel feed

After bruising rejection, bluebird and Bristol Myers Squibb land ide-cel priority review. But will it matter for the CVR?

5 years ago

#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap

5 years ago

#ESMO20: Pushing into frontline, Merck and Bristol Myers duke it out with new slate of GI cancer data

5 years ago

#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field

5 years ago

Immune Regulation, taking two clinical programs to 'reset' the immune system, nets $53M+ Series B

5 years ago

#ESMO20: 'As good as any PD-1 out there': Regeneron flashes PD-(L)1 lung cancer data to rival Merck

5 years ago

#ESMO20: AstraZeneca aims to spur PROfound shift in prostate cancer treatment with Lynparza OS data

5 years ago

#ESMO20: Eli Lilly shows off the data for its Verzenio success. Was it worth $18 billion?

5 years ago

#ESMO20: It’s not just Keytruda anymore — Merck spotlights 3 top early-stage cancer drugs

5 years ago

#ESMO20: Amgen team nails down solid early evidence of AMG 510’s potential for NSCLC, unlocking the door to a wave of KRAS programs

5 years ago

#ESMO20: Out to beat Tagrisso, J&J touts 100% ORR for EGFR bispecific/TKI combo — fueling a quick leap to PhIII

5 years ago

#ESMO20: Trodelvy data show that Gilead's $21B buyout may have been worth the big premium

5 years ago

#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?

5 years ago

#ESMO20: Look out Merck. Bristol Myers and Exelixis stake out their combo’s claim to best-in-class status for frontline kidney cancer

5 years ago

#ESMO20: Autolus provides glimpse of next-generation CAR-T program, showing early positive safety data

5 years ago

Seattle Genetics' Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer

5 years ago

#ESMO20: Alkermes offers their first snapshot of a benefit for their next-gen IL-2 drug. But why did 1 patient starve to death?

5 years ago

Pfizer matches Moderna with their full Covid-19 trial blueprint — AstraZeneca says it will unveil its protocol 'shortly'

5 years ago

#ESMO20: Regeneron, Sanofi eye another first for their PD-1 contender Libtayo with promising data for oncology niche

5 years ago

'The biggest inflection point ever': On R&D day, Moderna CEO Stéphane Bancel doubles down on vaccines and lays out a vision for a '40, 50'-drug biotech

5 years ago

Lava breaks prolonged silence with an $83M Series C and two I/O programs set for the clinic

5 years ago

Forget the IPO, Illumina is nearing a buyout of $1.9B liquid biopsy startup Grail — report

5 years ago

Metacrine, a Rich Heyman biotech targeting NASH and other liver diseases, raises $85M from IPO

5 years ago

Nearly two years after their narrow PhIII failure, Orphazyme gets speedy look at the FDA

5 years ago

First page Previous page 188 189 190191192 193 194 Next page Last page